Responses
Therapeutics/prevention
Cost-effectiveness study
Protease inhibitor monotherapy was non-inferior and cost-effective as maintenance therapy compared to triple therapy in viral load suppressed patients with HIV-1 infection
Compose a Response to This Article
Other responses
No responses have been published for this article.